{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T02:58:22Z","timestamp":1782788302874,"version":"3.54.5"},"reference-count":33,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2018,5,1]],"date-time":"2018-05-01T00:00:00Z","timestamp":1525132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,5,1]],"date-time":"2018-05-01T00:00:00Z","timestamp":1525132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Shionogi & Co., Ltd"},{"name":"Chugai Pharmaceutical Co., Ltd."},{"name":"Boehringer Ingelheim Japan, Inc."},{"name":"Daiichi Sankyo Co., Ltd."},{"DOI":"10.13039\/501100013170","name":"Ono Pharmaceutical Co., Ltd.","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100013170","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Astellas Pharma Inc"},{"DOI":"10.13039\/501100007132","name":"Otsuka Pharmaceutical Co., Ltd.","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100007132","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Pfizer Japan Inc."},{"name":"Taiho Pharmaceutical Co., Ltd."},{"name":"Taisho Toyama Pharmaceutical Co., Ltd."},{"name":"Japan Blood Products Organization"},{"DOI":"10.13039\/100010740","name":"Asahi Kasei Pharma Corporation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100010740","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Sumitomo Dainippon Pharma Co., Ltd."},{"name":"Meiji Seika Pharma Co., Ltd."},{"name":"Kyorin Pharmaceutical Co., Ltd."}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jiac-j.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Infection and Chemotherapy"],"published-print":{"date-parts":[[2018,5]]},"DOI":"10.1016\/j.jiac.2018.01.018","type":"journal-article","created":{"date-parts":[[2018,2,17]],"date-time":"2018-02-17T08:04:43Z","timestamp":1518854683000},"page":"325-329","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["In\u00a0vitro activity of various antibiotics against clinical strains of Legionella species isolated in Japan"],"prefix":"10.1016","volume":"24","author":[{"given":"Naoyuki","family":"Miyashita","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Intetsu","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Futoshi","family":"Higa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yosuke","family":"Aoki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiaki","family":"Kikuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masafumi","family":"Seki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiro","family":"Tateda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuko","family":"Maki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiro","family":"Uchino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiko","family":"Ogasawara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoe","family":"Kurachi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuya","family":"Ishikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshito","family":"Ishimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Izumo","family":"Kanesaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Kiyota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jiac.2018.01.018_bib1","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.jiac.2015.02.008","volume":"23","author":"Yanagihara","year":"2015","journal-title":"J\u00a0Infect Chemother"},{"key":"10.1016\/j.jiac.2018.01.018_bib2","doi-asserted-by":"crossref","first-page":"4046","DOI":"10.1128\/AAC.00663-13","article-title":"Nationwide surveillance of macrolide-resistant Mycoplasma pneumoniae infection in pediatric patients","volume":"57","author":"Kawai","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jiac.2018.01.018_bib3","doi-asserted-by":"crossref","first-page":"4624","DOI":"10.1128\/AAC.48.12.4624-4630.2004","article-title":"Characterization and molecular analysis of macrolide-resistant Mycoplasma pneumoniae clinical isolates obtained in Japan","volume":"48","author":"Matsuoka","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jiac.2018.01.018_bib4","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1128\/AAC.00779-07","article-title":"Increased macrolide resistance of Mycoplasma pneumoniae in pediatric patients with community-acquired pneumonia","volume":"52","author":"Morozumi","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jiac.2018.01.018_bib5","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1128\/AAC.00048-13","article-title":"Therapeutic efficacy of macrolides, minocycline, and tosufloxacin against macrolide-resistant Mycoplasma pneumoniae pneumonia in pediatric patients","volume":"57","author":"Kawai","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jiac.2018.01.018_bib6","doi-asserted-by":"crossref","first-page":"5181","DOI":"10.1128\/AAC.00737-13","article-title":"Macrolide-resistant Mycoplasma pneumoniae pneumonia in adolescents and adults: clinical findings, drug susceptibility and therapeutic efficacy","volume":"57","author":"Miyashita","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jiac.2018.01.018_bib7","first-page":"1007","article-title":"Legionella pneumophila. A cause of severe community-acquired pneumonia","volume":"100","author":"Falco","year":"1991","journal-title":"Chest"},{"key":"10.1016\/j.jiac.2018.01.018_bib8","doi-asserted-by":"crossref","first-page":"317","DOI":"10.2169\/internalmedicine.52.8830","article-title":"Etiology and factors contributing to the severity and mortality of community-acquired pneumonia","volume":"52","author":"Ishiguro","year":"2013","journal-title":"Intern Med"},{"key":"10.1016\/j.jiac.2018.01.018_bib9","doi-asserted-by":"crossref","first-page":"2869","DOI":"10.1093\/jac\/dku196","article-title":"Isolation of ciprofloxacin-resistant Legionella pneumophila in a patient with severe pneumonia","volume":"58","author":"Bruin","year":"2014","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.jiac.2018.01.018_bib10","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1093\/jac\/46.4.589","article-title":"Evaluation of a human monocytic cell line THP-1 model for assay of the intracellular activities of antimicrobial agents against Legionella pneumophila","volume":"46","author":"Takemura","year":"2000","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.jiac.2018.01.018_bib11","first-page":"364","article-title":"Antimicrobial activity surveillance of various clinical isolates to tosufloxacin and other fluoroquinolones","volume":"53","author":"Sato","year":"2005","journal-title":"Jpn J Chemother"},{"key":"10.1016\/j.jiac.2018.01.018_bib12","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1093\/jac\/dki391","article-title":"In\u00a0vitro activity of pazufloxacin, tosufloxacin and other quinolones against Legionella species","volume":"56","author":"Higa","year":"2005","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.jiac.2018.01.018_bib13","first-page":"718","article-title":"New susceptibility testing medium (B-SYE agar) for Legionella and Legionella-like organisms","volume":"32","author":"Sawatari","year":"1984","journal-title":"Chemotherapy (Tokyo)"},{"key":"10.1016\/j.jiac.2018.01.018_bib14","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1128\/AAC.30.5.743","article-title":"Inhibition of Legionella pneumophila multiplication within human macrophages by antimicrobial agents","volume":"30","author":"Vild\u00e9","year":"1986","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jiac.2018.01.018_bib15","doi-asserted-by":"crossref","first-page":"63","DOI":"10.2165\/00003495-199346010-00005","article-title":"Treatment of Legionnaries' disease: current recommendations","volume":"46","author":"Roig","year":"1983","journal-title":"Drugs"},{"key":"10.1016\/j.jiac.2018.01.018_bib16","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1378\/chest.125.6.2135","article-title":"Levofloxacin efficacy in the treatment of community-acquired Legionellosis","volume":"125","author":"Yu","year":"2004","journal-title":"Chest"},{"key":"10.1016\/j.jiac.2018.01.018_bib17","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1086\/428059","article-title":"Clinical outcome for hospitalized patients with Legionella pneumonia in the antigenuria era: the influence of levofloxacin therapy","volume":"40","author":"Mykietiuk","year":"2005","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jiac.2018.01.018_bib18","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1086\/428049","article-title":"Antimicrobial chemotherapy for Legionnaries disease: levofloxacin versus macrolides","volume":"40","author":"Blazquez Garrido","year":"2005","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jiac.2018.01.018_bib19","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1378\/chest.128.3.1401","article-title":"Fluoroquinolones vs macrolides in the treatment of Legionnaries disease","volume":"128","author":"Sabria","year":"2005","journal-title":"Chest"},{"key":"10.1016\/j.jiac.2018.01.018_bib20","doi-asserted-by":"crossref","first-page":"353","DOI":"10.2169\/internalmedicine.46.6006","article-title":"Intravenous ciprofloxacin versus erythromycin in the treatment of Legionella pneumonia","volume":"46","author":"Haranaga","year":"2007","journal-title":"Intern Med"},{"key":"10.1016\/j.jiac.2018.01.018_bib21","first-page":"495","article-title":"Macrolides versus quinolones in Legionella pneumonia: results from the community-acquired pneumonia organization international study","volume":"14","author":"Griffin","year":"2010","journal-title":"Int J Tuberc Lung Dis"},{"key":"10.1016\/j.jiac.2018.01.018_bib22","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1378\/chest.119.4.1114","article-title":"Steady-state plasma and intrapulmonary concentrations of levofloxacin and ciprofloxacin in healthy adult subjects","volume":"119","author":"Gotfried","year":"2001","journal-title":"Chest"},{"key":"10.1016\/j.jiac.2018.01.018_bib23","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/j.jiac.2017.09.001","article-title":"Clinical presentation of Legionella pneumonia: evaluation of clinical scoring systems and therapeutic efficacy","volume":"23","author":"Miyashita","year":"2017","journal-title":"J\u00a0Infect Chemother"},{"key":"10.1016\/j.jiac.2018.01.018_bib24","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.jiac.2014.05.002","article-title":"Efficacy and safety of garenoxacin tablets on clinically diagnosed atypical pneumonia: post marketing surveillance in Japan","volume":"20","author":"Izumikawa","year":"2014","journal-title":"J\u00a0Infect Chemother"},{"key":"10.1016\/j.jiac.2018.01.018_bib25","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.jiac.2014.05.003","article-title":"Efficacy and safety of garenoxacin tablets on bacterial pneumonia: post marketing surveillance in Japan","volume":"20","author":"Izumikawa","year":"2014","journal-title":"J\u00a0Infect Chemother"},{"key":"10.1016\/j.jiac.2018.01.018_bib26","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1128\/AAC.36.10.2293","article-title":"In\u00a0vitro activity of T-3761, a new fluoroquinolone","volume":"36","author":"Muratani","year":"1992","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jiac.2018.01.018_bib27","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1128\/AAC.37.3.384","article-title":"In\u00a0vitro and in\u00a0vivo antibacterial activities of T-3761, a new quinolone derivative","volume":"37","author":"Fukuoka","year":"1993","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jiac.2018.01.018_bib28","doi-asserted-by":"crossref","first-page":"3351","DOI":"10.1128\/AAC.44.12.3351-3356.2000","article-title":"Antibacterial spectrum of a novel des-fluoro(6) quinolone, BMS-284756","volume":"44","author":"Fung-Tomc","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jiac.2018.01.018_bib29","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/S0732-8893(01)00285-1","article-title":"In\u00a0vitro susceptibility study of BMS-284756 against Legionella species","volume":"41","author":"Dubois","year":"2001","journal-title":"Diag Microbiol Infect Dis"},{"key":"10.1016\/j.jiac.2018.01.018_bib30","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1086\/341087","article-title":"Distribution of legionella species and serogroups isolated by culture in patients with sporadic community-acquired legionellosis: an international collaborative survey","volume":"186","author":"Yu","year":"2002","journal-title":"J\u00a0Inefct Dis"},{"key":"10.1016\/j.jiac.2018.01.018_bib31","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1093\/jac\/dkg191","article-title":"Legionnaries' disease: a rational approach to therapy","volume":"51","author":"Roig","year":"2003","journal-title":"J\u00a0Antomicrob Chemother"},{"key":"10.1016\/j.jiac.2018.01.018_bib32","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1128\/JCM.42.1.458-460.2004","article-title":"Clinical and environmental distributions of Legionella strains in France are different","volume":"42","author":"Doleans","year":"2004","journal-title":"J\u00a0Clin Microbiol"},{"key":"10.1016\/j.jiac.2018.01.018_bib33","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.ijmm.2014.04.004","article-title":"Molecular typing of Legionella pneumophila serogroup 1 clinical strains isolated in Italy","volume":"304","author":"Frontana","year":"2014","journal-title":"Int J Med Microbiol"}],"container-title":["Journal of Infection and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1341321X18300485?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1341321X18300485?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T18:57:07Z","timestamp":1761159427000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1341321X18300485"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5]]},"references-count":33,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,5]]}},"alternative-id":["S1341321X18300485"],"URL":"https:\/\/doi.org\/10.1016\/j.jiac.2018.01.018","relation":{},"ISSN":["1341-321X"],"issn-type":[{"value":"1341-321X","type":"print"}],"subject":[],"published":{"date-parts":[[2018,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"In\u00a0vitro activity of various antibiotics against clinical strains of Legionella species isolated in Japan","name":"articletitle","label":"Article Title"},{"value":"Journal of Infection and Chemotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jiac.2018.01.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}